Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency
Calidi Biotherapeutics, Inc. (CLDI) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency SAN DIEGO, September 25, 2026 – Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the developm
- Exchange
- NYSE American
- Kind
- deficiency
- Rule
- Section 1003(a)(ii)
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The notice creates immediate compliance risk, likely prompting short sellers and volatility. Acceptance of a plan could mitigate downside.
Market read
Compliance notice is a material corporate event for CLDI, affecting price and investor sentiment.
What to watch
Potential for a capital raise or strategic partnership to quickly boost equity.
Background
Calidi Biotherapeutics (CLDI) is a biotech developing oncolytic virus therapies. The NYSE American requires $4M equity for companies with losses; CLDI fell short.
Ticker impact
Calidi Biotherapeutics received a NYSE American notice of stockholders' equity deficiency and must submit a compliance plan by Oct 21, 2026 or face delisting.
downside pressure until plan acceptance; possible short-term volatility.
Listing deficiency is material for a small-cap biotech; market reacts to compliance uncertainty.
Market effects
Highlights compliance risk for small-cap biotech listings on NYSE American.
US small-cap biotech sector may see heightened scrutiny.
Limited to US-listed biotech investors.
Counterpoint
If management secures a robust compliance plan, the stock could rebound on relief rally.
Key entities
- Regulatory BodyNYSE American
Exchange enforcing continued listing standards.
- CompanyCalidi Biotherapeutics, Inc.
Biotech issuer facing equity deficiency.
